Isis Pharmaceuticals Advances ISIS-SMN Rx in Infants and Children with Spinal Muscular Atrophy

[PR Newswire] – CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (ISIS) announced today that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMNRx in children with spinal muscular atroph more

View todays social media effects on ISIS

View the latest stocks trending across Twitter. Click to view dashboard

See who Isis is hiring next, click here to view